Published in Int J Gynecol Cancer on November 06, 2007
Can we safely target the WNT pathway? Nat Rev Drug Discov (2014) 2.31
Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res (2010) 1.22
WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway. Mol Cancer Res (2012) 1.21
Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res (2011) 1.15
Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget (2015) 1.07
Integrin regulation of beta-catenin signaling in ovarian carcinoma. J Biol Chem (2011) 1.06
Pathway-based classification of cancer subtypes. Biol Direct (2012) 1.05
Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochem J (2011) 1.05
Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN. PLoS One (2011) 1.04
Wnt and hedgehog gene pathway expression in serous ovarian cancer. Int J Gynecol Cancer (2011) 1.02
Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? World J Stem Cells (2014) 1.01
Changes in gene expression and cellular architecture in an ovarian cancer progression model. PLoS One (2011) 1.01
Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Sci (2014) 1.00
Telomere length and genetic variation in telomere maintenance genes in relation to ovarian cancer risk. Cancer Epidemiol Biomarkers Prev (2012) 1.00
Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovarian Res (2014) 0.98
Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden. Front Oncol (2014) 0.98
Filamin A interacting protein 1-like inhibits WNT signaling and MMP expression to suppress cancer cell invasion and metastasis. Int J Cancer (2014) 0.98
No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer. BMC Cancer (2009) 0.93
Matrix rigidity activates Wnt signaling through down-regulation of Dickkopf-1 protein. J Biol Chem (2012) 0.93
Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer (2013) 0.89
An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population. Mol Diagn Ther (2014) 0.88
WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene (2014) 0.87
Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth. Anticancer Drugs (2011) 0.86
Expression of the Wnt antagonist DKK3 is frequently suppressed in sporadic epithelial ovarian cancer. J Cancer Res Clin Oncol (2010) 0.86
Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer. Gynecol Oncol (2012) 0.86
TC-1 (C8orf4) expression is correlated with differentiation in ovarian carcinomas and might distinguish metastatic ovarian from metastatic colorectal carcinomas. Virchows Arch (2013) 0.85
Secreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers. BMC Cell Biol (2012) 0.85
An integrative approach to identifying cancer chemoresistance-associated pathways. BMC Med Genomics (2011) 0.85
Wnt2 promotes non-small cell lung cancer progression by activating WNT/β-catenin pathway. Am J Cancer Res (2015) 0.83
Development of anticancer agents targeting the Wnt/β-catenin signaling. Am J Cancer Res (2015) 0.83
β-catenin/Tcf-signaling appears to establish the murine ovarian surface epithelium (OSE) and remains active in selected postnatal OSE cells. BMC Dev Biol (2012) 0.81
The role of the Wnt signaling pathway in cancer stem cells: prospects for drug development. Res Rep Biochem (2014) 0.80
Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer (2016) 0.79
Pathway Relevance Ranking for Tumor Samples through Network-Based Data Integration. PLoS One (2015) 0.77
Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma. Oncotarget (2016) 0.77
KIAA0101, a target gene of miR-429, enhances migration and chemoresistance of epithelial ovarian cancer cells. Cancer Cell Int (2016) 0.75
Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/β-catenin pathway. Oncotarget (2016) 0.75
Inhibition of ovarian cancer proliferation and invasion by pachymic acid. Int J Clin Exp Pathol (2015) 0.75
Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling. J Biol Chem (2016) 0.75
Geraniol Inhibits Endometrial Carcinoma via Downregulating Oncogenes and Upregulating Tumour Suppressor Genes. Indian J Clin Biochem (2016) 0.75
Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer. Oncotarget (2016) 0.75
Clinical significance and biological role of Wnt10a in ovarian cancer. Oncol Lett (2017) 0.75
Potential lung carcinogenicity induced by chronic exposure to PM2.5 in the rat. Environ Sci Pollut Res Int (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science (1997) 8.99
Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta (2003) 7.85
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res (1998) 5.80
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet (2000) 5.26
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell (2004) 4.98
Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA (2004) 3.81
Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell (2002) 3.42
Pygopus and Legless target Armadillo/beta-catenin to the nucleus to enable its transcriptional co-activator function. Nat Cell Biol (2004) 2.90
Granulosa cell tumor of the ovary. J Clin Oncol (2003) 2.70
Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem (2003) 2.35
Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res (2006) 2.29
Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res (1998) 2.27
FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J (2004) 2.24
A new nuclear component of the Wnt signalling pathway. Nat Cell Biol (2002) 2.23
The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res (2004) 2.16
Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res (2006) 2.16
Pygopus, a nuclear PHD-finger protein required for Wingless signaling in Drosophila. Development (2002) 2.11
Endothelial and steroidogenic cell migration are regulated by WNT4 in the developing mammalian gonad. Development (2003) 2.10
Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res (1998) 2.01
Follistatin operates downstream of Wnt4 in mammalian ovary organogenesis. Dev Dyn (2004) 1.96
A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin. FEBS Lett (1999) 1.88
Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res (2001) 1.87
Molecular biology of colorectal cancer. Curr Probl Cancer (1998) 1.70
Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn (2006) 1.70
Recent advances in the pathology and classification of ovarian sex cord-stromal tumors. Int J Gynecol Pathol (2006) 1.70
Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res (2005) 1.69
Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol (1997) 1.63
beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol (1999) 1.55
Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev (2002) 1.54
Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer (2004) 1.54
Misregulated Wnt/beta-catenin signaling leads to ovarian granulosa cell tumor development. Cancer Res (2005) 1.51
Pygopus and legless provide essential transcriptional coactivator functions to armadillo/beta-catenin. Curr Biol (2005) 1.50
Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res (2003) 1.46
Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol (2001) 1.37
Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer (2003) 1.35
beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer (1999) 1.31
Epithelial-mesenchymal transition in gastric cancer (Review). Int J Oncol (2005) 1.24
Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. Cancer Sci (2004) 1.23
beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol (2001) 1.20
Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt-2b, and frizzled-4 mRNAs. Endocrinology (2002) 1.20
Pygopus residues required for its binding to Legless are critical for transcription and development. J Biol Chem (2003) 1.15
Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am J Pathol (2002) 1.14
Dominant-stable beta-catenin expression causes cell fate alterations and Wnt signaling antagonist expression in a murine granulosa cell tumor model. Cancer Res (2006) 1.10
Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene (2001) 1.07
beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer (2005) 1.06
Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer. Clin Cancer Res (2006) 1.04
Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas. Jpn J Cancer Res (1999) 1.01
beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol (2003) 1.00
Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett (2003) 0.95
Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma. Int J Surg Pathol (2002) 0.92
Loss of beta-catenin is associated with poor survival in ovarian carcinomas. Int J Gynecol Pathol (2004) 0.89
Specific keynote: genome copy number abnormalities in ovarian cancer. Gynecol Oncol (2003) 0.89
Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours. Br J Cancer (2006) 0.88
NSAIDs and gastrointestinal cancer prevention. Drugs (2002) 0.88
Biological relevance of E-cadherin-catenin complex proteins in primary epithelial ovarian tumours. Gynecol Obstet Invest (2005) 0.78
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol (2000) 6.06
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A (2001) 5.57
Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet (2001) 5.09
Informed consent for clinical trials: a comparative study of standard versus simplified forms. J Natl Cancer Inst (1998) 3.89
Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med (1989) 2.70
Sources of absorption and scattering contrast for near-infrared optical mammography. Acad Radiol (2001) 2.66
Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst (1996) 2.30
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol (1995) 2.26
Spectroscopy enhances the information content of optical mammography. J Biomed Opt (2002) 1.83
Lysosome-associated membrane proteins h-LAMP1 (CD107a) and h-LAMP2 (CD107b) are activation-dependent cell surface glycoproteins in human peripheral blood mononuclear cells which mediate cell adhesion to vascular endothelium. Cell Immunol (1996) 1.36
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol (2010) 1.15
Expression of secreted Wnt antagonists in gastrointestinal tissues: potential role in stem cell homeostasis. J Clin Pathol (2005) 1.15
Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women. Obstet Gynecol (2001) 1.14
A Wnt kinase network alters nuclear localization of TCF-1 in colon cancer. Oncogene (2009) 1.07
Identification of mutations in two major mRNA isoforms of the Chediak-Higashi syndrome gene in human and mouse. Hum Mol Genet (1997) 1.06
Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer (2000) 0.98
Fatal leukoencephalopathy in a patient with non-Hodgkin's lymphoma treated with CHOP chemotherapy and high-dose steroids. Am J Med Sci (1998) 0.95
Evidence for the induction of apoptosis by endosulfan in a human T-cell leukemic line. Mol Cell Biochem (2000) 0.95
Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model. Gynecol Oncol (2000) 0.93
Young age as a prognostic factor in cervical cancer: results of a population-based study. Am J Obstet Gynecol (1999) 0.91
A human gene homologous to the formin gene residing at the murine limb deformity locus: chromosomal location and RFLPs. Am J Hum Genet (1991) 0.90
Nonsteroidal antiinflammatory drugs and colorectal cancer. Epidemiol Rev (1996) 0.89
Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix. Obstet Gynecol (2001) 0.89
Cervical cancer with paraaortic metastases: significance of residual paraaortic disease after surgical staging. Gynecol Oncol (1998) 0.87
Small bowel obstruction following radical hysterectomy: risk factors, incidence, and operative findings. Gynecol Oncol (1994) 0.87
HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3. Br J Cancer (2003) 0.86
Natural history of the minimally abnormal Papanicolaou smear. Obstet Gynecol (1992) 0.86
Chediak-Higashi lymphoblastoid cell lines: granule characteristics and expression of lysosome-associated membrane proteins. Clin Immunol Immunopathol (1992) 0.86
Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer. J Am Coll Surg (2001) 0.86
Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Int J Gynecol Cancer (2004) 0.85
Surgical and nonsurgical management of primary and metastatic liver tumors. Am Surg (1998) 0.85
Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features. Mol Pathol (2003) 0.84
Does human papillomavirus have a role in cancers of the uterine corpus? Gynecol Oncol (1999) 0.84
Social drinking and the immune response: impairment of lymphokine-activated killer activity. Am J Med Sci (1994) 0.83
Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol (1999) 0.83
Intent-to-treat analysis of stage Ib and IIa cervical cancer in the United States: radiotherapy or surgery 1988-1995. Obstet Gynecol (2001) 0.81
Primary invasive carcinoma of the vagina: treatment with interstitial brachytherapy. Cancer (2001) 0.81
Informed consent, cancer, and truth in prognosis. N Engl J Med (1994) 0.81
Interstitial brachytherapy in the treatment of advanced and recurrent vulvar cancer. Am J Obstet Gynecol (1999) 0.80
Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug: ability to inhibit post-radical pelvic surgery adhesions in a porcine model. Gynecol Oncol (1993) 0.80
Effect of levamisole on major histocompatibility complex class I expression in colorectal and breast carcinoma cell lines. Cancer (1993) 0.80
Single-visit program for cervical cancer prevention in a high-risk population. Obstet Gynecol (1995) 0.80
Positional cloning of the Chediak-Higashi syndrome gene: genetic mapping of the beige locus on mouse chromosome 13. J Investig Med (1996) 0.79
The Gore-Tex Surgical Membrane: effectiveness as a barrier to inhibit postradical pelvic surgery adhesions in a porcine model. Gynecol Oncol (1992) 0.79
Protein kinase C isoform expression and activity alter paclitaxel resistance in vitro. Gynecol Oncol (1999) 0.78
Idiopathic CD4+ T-lymphocytopenia and recurrent vulvar intraepithelial neoplasia. Obstet Gynecol (1994) 0.77
The effects of anticancer chemotherapeutic drugs on cognitive function and other neuropsychiatric dimensions in breast cancer patients. Methods Find Exp Clin Pharmacol (2003) 0.77
Effectiveness of two barriers at inhibiting post-radical pelvic surgery adhesions. Gynecol Oncol (1993) 0.76
Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma. Int J Gynecol Cancer (2007) 0.76
The question remains: oncology and primary care. J Clin Oncol (1997) 0.75
The gene for the human mast cell high-affinity IgE receptor alpha chain: chromosomal localization to Iq21-q23 and RFLP analysis. Am J Hum Genet (1989) 0.75
Underinsurance in America. N Engl J Med (1992) 0.75
Effect of angiotensin II on vascular resistance in whole-body perfused dogfish. Comp Biochem Physiol C (1982) 0.75
Transfusion therapy in sickle cell disease patients: methods and acute indications. J La State Med Soc (1993) 0.75
Prevention of cervical cancer with vaccines. Curr Oncol Rep (2001) 0.75
Cell surface expression of lysosome-associated membrane protein-2 (lamp2) and CD63 as markers of in vivo platelet activation in malignancy. Eur J Haematol (1995) 0.75
Quantitation of CD62, soluble CD62, and lysosome-associated membrane proteins 1 and 2 for evaluation of the quality of stored platelet concentrates. Transfusion (1995) 0.75
Effect of angiotensins and epinephrine on vascular resistance of isolated dogfish gut. Am J Physiol (1978) 0.75
Crisis in medical research. Acad Med (1997) 0.75
Human immunodeficiency virus testing in patients with invasive cervical carcinoma: a prospective trial of the gynecologic oncology group. Int J Gynecol Cancer (2006) 0.75
The role of the hematologist/oncologist as a primary care provider. Am J Med Sci (1994) 0.75